The Gynecological Cancer Tissue Bank [Formation Of The Gynaecological Cancer Tissue Bank], Canada

Certification Status: Documents Required

Registration Status: Completed

Objective: The purpose of the Gynecological Cancer Tissue Bank is to improve knowledge about gynecological cancer, by making available to scientists across Canada large numbers of gynecological tumour specimens and normal control tissues for studies of cancer biology, detection and treatment. To this end, pathologist, clinicians and cancer researchers in British Columbia have formed the Gynecological Cancer tissue bank to collect tissue from gynecological cancers. Research to determine how gynecologic cancers begin, what causes them, how to treat them and the long term effects of treatments is urgently needed. The researchers at the British Columbia Ovarian Cancer Research Program (OvCaRe) are conducting such research.

Registered Biobank Name	The Gynecological Cancer Tissue Bank [Formation Of The Gynaecological Cancer Tissue Bank] (OvCaRe)
Biobank Leader	Jessica Kwon
Country	Canada
Email for biobank inquiries	jkwon@bccrc.ca
Principal Investigator	Jessica McAlpine
Website
User Type Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper	Poly - Collection aimed at supporting undetermined, multiple users with ethics approved research projects, through a defined access/application mechanism.

Biospecimen Collected:

Cohort Highlights

100 cases Next Generation Sequencing assay to detect all classes of genetic variant in Lung Cancer using a single Diagnostic test.
200 cases Colorectal TMA for QC purposes in support of study of tumor infiltrating lymphocytes in ovarian cancer tissues.
Build 300 cases breast cancer TMA containing primary tumour and matched metastatic LN for various subtypes (luminal, HER2, Triple negative). Start with Triple negatives.
125 cases Breast tumour and metastatic lymph nodes in breast cancer cases with outcomes of metastasis to lung or bone.
100 cases of rare tumours - fibrolamellar hepatocellular carcinoma. FFPE, frozen, BC.
200 cases of FFPE tissue sections from breast, lung adenocarcinoma, and lung squamous cell carcinoma with matching normal tissue (only pathology data requested).